ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Cancer
Prostatic Cancer

Adenocarcinoma trials near London, England, GBR:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

London, United Kingdom and 155 other locations

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

London, London, City of, United Kingdom and 167 other locations

participants to treat locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA).T...

Enrolling
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Drug: Budigalimab
Drug: Oxaliplatin

Phase 2

AbbVie
AbbVie

London, Greater London, United Kingdom and 44 other locations

resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....

Enrolling
Gastroesophageal Adenocarcinoma
Drug: 5-Fluorouracil (5-FU)
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

Headington, United Kingdom and 67 other locations

Recently updated

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

London, United Kingdom and 124 other locations

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: AZD0901
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

London, United Kingdom and 43 other locations

with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...

Begins enrollment in 1 month
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Drug: Nivolumab
Drug: Pumitamig

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

London, London, City of, United Kingdom and 157 other locations

in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma...

Enrolling
Locally Advanced Gastric Adenocarcinoma
MSI-H/dMMR Gastroesophageal-junction Cancer
Drug: Single agent zimberelimab
Drug: Combination zimberelimab + domvanalimab

Phase 2

Royal Marsden NHS Foundation Trust

London, United Kingdom and 8 other locations

with chemotherapy in treating adults with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: zolbetuximab

Phase 3

Astellas
Astellas

London, United Kingdom and 164 other locations

An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is M...

Enrolling
Adenocarcinoma - GEJ
Cancer of Esophagus
Drug: Temozolomide 3 month
Drug: Temozolomide 50mg/m2/day

Phase 2

University of Southampton

Cambridge, Cambridgeshire, United Kingdom

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems